Abstract
Herpes zoster (HZ) represents an economic and humanistic burden for healthcare systems. The incidence of HZ and its complications —such as postherpetic neuralgia (PHN)— increase with age. In Switzerland, two HZ vaccines are available: the adjuvanted recombinant zoster vaccine (RZV) and the zoster live vaccine. RZV is approved for adults aged ≥50 years and immunocompromised adults. We assessed the cost-effectiveness of vaccinating adults aged ≥65 years with RZV versus no vaccination, in Switzerland.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
